Home | Industry Information | Business News | Browse by Publication | T | The Journal of Critical Illness

Rifampin and rifabutin: what to expect with drug interactions. (Quick Take).

Publication: The Journal of Critical Illness
Publication Date: 01-JUN-03
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Rifampin has been associated with numerous clinically significant drug interactions. (1-4) In the March 1998 issue of The Journal of Critical Illness, Drs Strayhorn, Baciewicz, and Self reviewed rifampin-drug interactions. (5)

Since then, several more rifampin- and rifabutin-drug have and...

View more below

You can view this article PLUS...

  • Hundreds of the most trusted magazines, newspapers, newswires, and journals (see list)
  • Business news from North America and around the World
  • More than 10 years of article archives
  • Unlimited Access at any time - ONLINE and all in ONE place

Now for a Limited Time, try Goliath Business News - Free for 7 Days!
Tell Me More   Terms and Conditions
Already a subscriber?
Log in to view full article
Purchase this article for $4.95

...interactions been reported, we recently reviewed those studies and clinical observations in a published article. (6) Here we have summarized key points from that article, with an emphasis on the tables.

Rifampin is a potent inducer of cytochrome P-450 (GYP) oxidative enzymes. A few examples of well-documented, clinically sigrnficant interactions are shown in Table 1. Other potentially important interactions are listed in Table 2. More recently reported rifampin-drug interactions are summarized in Table 3.

Rifampin is an effective inducer of both the hepatic and intestinal GYP enzyme system and P-glycoprotein (P-gp) transport system. Schuetz and colleagues (7) found that rifampin intracellular concentrations strongly correlated with P-gp levels and, thus, the extent to which rifampin was able to induce GYP3A. P-gp, a transmembrane protein, is a member of the adenosine triphosphate--binding cassette family, which is a group of molecules that control concentrations of both endogenous and exogenous substances across cell membranes by functioning as cellular efflux pumps. (7)

Rifabutin use continues to increase in HIV-infected patients, and new drug interactions with this agent are being reported. While rifabutindrug interactions are usually less dramatic than rifampin-drug interactions, many are clinically important. Rifabutin- and rifampin-drug interactions are compared in Table 4.

When you prescribe therapy with either rifampin or rifabutin, it is prudent to screen for drug interactions. To avoid reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, you need to be aware of these interactions and manage them appropriately....

NOTE: All illustrations and photos have been removed from this article.



Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.